Cargando…
Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis
BACKGROUND: Multiple clinical trials were conducted to evaluate the efficacy of neoadjuvant therapy in esophageal cancer but exhibited mixed results, indicating that the efficacy of neoadjuvant therapy remains controversial in the treatment of esophageal cancer. Our study was conducted to investigat...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011204/ https://www.ncbi.nlm.nih.gov/pubmed/35434045 http://dx.doi.org/10.21037/atm-22-577 |
_version_ | 1784687635349897216 |
---|---|
author | Yu, Yongkui Xu, Lei Chen, Xiankai Li, Haomiao Liu, Qi Zhang, Ruixiang Xie, Hounai Chen, Yongfeng Yuan, Ling Tan, Bo Li, Yin Xing, Wenqun |
author_facet | Yu, Yongkui Xu, Lei Chen, Xiankai Li, Haomiao Liu, Qi Zhang, Ruixiang Xie, Hounai Chen, Yongfeng Yuan, Ling Tan, Bo Li, Yin Xing, Wenqun |
author_sort | Yu, Yongkui |
collection | PubMed |
description | BACKGROUND: Multiple clinical trials were conducted to evaluate the efficacy of neoadjuvant therapy in esophageal cancer but exhibited mixed results, indicating that the efficacy of neoadjuvant therapy remains controversial in the treatment of esophageal cancer. Our study was conducted to investigate the value of neoadjuvant therapy in patients with esophageal cancer with supraclavicular lymph node metastases. METHODS: We retrospectively enrolled 231 patients who had resectable esophageal squamous cell carcinoma (ESCC) with supraclavicular lymph node metastases from June 2008 to November 2018. All patients were divided into three groups: the neoadjuvant therapy combined with surgery (Neo + S) group, the radical chemoradiotherapy (CRT) group, and the single radiotherapy (RT) group. Propensity score matching (PSM) was conducted to exclude the impact of potential interferences. Kaplan-Meier analysis, the log-rank test, and competitive risk model analysis were used to assess the efficacy of different therapeutic methods. RESULTS: Patients in the Neo + S group had a better 3-year survival rate (72.0% vs. 35.8%; P=0.005), progression-free survival (PFS) (24 vs. 14 months; P<0.0001), and lower 3-year tumor-specific mortality risk (25.1% vs. 53.7%; P=0.005) than those in the CRT group. Furthermore, patients in the CRT group had a better 3-year survival (30.1% vs. 18.6%; P=0.012) and lower 3-year tumor-specific mortality risk (57.9% vs. 76.8%; P=0.011) than those in the RT group. Additionally, the supraclavicular lymph node metastasis rate was higher than the mediastinal lymph node metastasis rate in patients with upper esophageal cancer compared to middle and lower esophageal cancer CONCLUSIONS: Neoadjuvant chemotherapy combined with surgery showed better efficacy than radical CRT in patients who had resectable ESCC with supraclavicular lymph nodes metastasis. Supraclavicular lymph nodes are more likely to be regional lymph nodes for upper and middle esophageal cancer. |
format | Online Article Text |
id | pubmed-9011204 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-90112042022-04-16 Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis Yu, Yongkui Xu, Lei Chen, Xiankai Li, Haomiao Liu, Qi Zhang, Ruixiang Xie, Hounai Chen, Yongfeng Yuan, Ling Tan, Bo Li, Yin Xing, Wenqun Ann Transl Med Original Article BACKGROUND: Multiple clinical trials were conducted to evaluate the efficacy of neoadjuvant therapy in esophageal cancer but exhibited mixed results, indicating that the efficacy of neoadjuvant therapy remains controversial in the treatment of esophageal cancer. Our study was conducted to investigate the value of neoadjuvant therapy in patients with esophageal cancer with supraclavicular lymph node metastases. METHODS: We retrospectively enrolled 231 patients who had resectable esophageal squamous cell carcinoma (ESCC) with supraclavicular lymph node metastases from June 2008 to November 2018. All patients were divided into three groups: the neoadjuvant therapy combined with surgery (Neo + S) group, the radical chemoradiotherapy (CRT) group, and the single radiotherapy (RT) group. Propensity score matching (PSM) was conducted to exclude the impact of potential interferences. Kaplan-Meier analysis, the log-rank test, and competitive risk model analysis were used to assess the efficacy of different therapeutic methods. RESULTS: Patients in the Neo + S group had a better 3-year survival rate (72.0% vs. 35.8%; P=0.005), progression-free survival (PFS) (24 vs. 14 months; P<0.0001), and lower 3-year tumor-specific mortality risk (25.1% vs. 53.7%; P=0.005) than those in the CRT group. Furthermore, patients in the CRT group had a better 3-year survival (30.1% vs. 18.6%; P=0.012) and lower 3-year tumor-specific mortality risk (57.9% vs. 76.8%; P=0.011) than those in the RT group. Additionally, the supraclavicular lymph node metastasis rate was higher than the mediastinal lymph node metastasis rate in patients with upper esophageal cancer compared to middle and lower esophageal cancer CONCLUSIONS: Neoadjuvant chemotherapy combined with surgery showed better efficacy than radical CRT in patients who had resectable ESCC with supraclavicular lymph nodes metastasis. Supraclavicular lymph nodes are more likely to be regional lymph nodes for upper and middle esophageal cancer. AME Publishing Company 2022-03 /pmc/articles/PMC9011204/ /pubmed/35434045 http://dx.doi.org/10.21037/atm-22-577 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Yu, Yongkui Xu, Lei Chen, Xiankai Li, Haomiao Liu, Qi Zhang, Ruixiang Xie, Hounai Chen, Yongfeng Yuan, Ling Tan, Bo Li, Yin Xing, Wenqun Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis |
title | Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis |
title_full | Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis |
title_fullStr | Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis |
title_full_unstemmed | Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis |
title_short | Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis |
title_sort | neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011204/ https://www.ncbi.nlm.nih.gov/pubmed/35434045 http://dx.doi.org/10.21037/atm-22-577 |
work_keys_str_mv | AT yuyongkui neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis AT xulei neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis AT chenxiankai neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis AT lihaomiao neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis AT liuqi neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis AT zhangruixiang neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis AT xiehounai neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis AT chenyongfeng neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis AT yuanling neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis AT tanbo neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis AT liyin neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis AT xingwenqun neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis |